GEN Exclusives

More »

GEN News Highlights

More »
Dec 6, 2010

UCB to Utilize Activiomics’ Proteomics Platform in Inflammatory Disease Research

  • UCB will employ Activiomics Tiquas (targeted in-depth quantification of cell signaling)  phosphoproteomics platform to elucidate signaling mechanisms of its therapeutic antibodies. Tiquas quantifies global kinase activity without the need for labeling or antibody isolation. It profiles and cross-compares phosphopeptides, ensuring accurate and reproducible data, Activiomics points out.

    The technology works by using a protease to break down a cell or tissue extract into peptide fragments. Phosphopeptide enrichment, mass spectrometry, and Tiquas software allow thousands of phosphopeptides to be quantified, the firm adds.

    “We have engaged with Activiomics because we recognize that their Tiquas technology has advantages for our inflammatory program over other methods available,” says Simon Lamb, project leader at UCB. “It is quantitative, label free, and applicable to cell and tissue samples. This technology will enable us to better understand cell signaling mechanisms of our therapeutic antibodies and could enable us to identify important biomarkers.”

    UCB is developing antibodies and small molecules to treat a range of autoimmune diseases including Crohn disease, rheumatoid arthritis, and systemic lupus erythematosus. The company is targeting molecules that regulate the immune system’s inappropriate response to the environmental or intrinsic factors that trigger inflammatory disease.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?